Media - Ironwood Pharmaceuticals

Media

Home
Media

Meredith Kaya

Vice President, Investor Relations and Corporate Communications

617.374.5082

mkaya@ironwoodpharma.com

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

bcalitri@ironwoodpharma.com

Sort by Year

August 6, 2018

Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update

July 23, 2018

Ironwood Pharmaceuticals to Host Second Quarter 2018 Investor Update Call

July 16, 2018

Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

June 23, 2018

Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact on Metabolic and Cardiovascular Clinical Endpoints at the American Diabetes Association’s 78th Scientific Sessions

June 21, 2018

Ironwood Pharmaceuticals Initiates Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease

June 20, 2018

Ironwood Pharmaceuticals to Highlight Clinical and Preclinical Data for Praliciguat at the American Diabetes Association’s 78th Scientific Sessions

June 7, 2018

Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease

June 6, 2018

Ironwood Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

June 5, 2018

Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week® 2018

May 31, 2018

Ironwood Pharmaceuticals Announces Results of 2018 Annual Meeting of Shareholders

May 23, 2018

Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week® 2018

May 14, 2018

Ironwood Pharmaceuticals Sends Letter to Shareholders Highlighting Director Nominees

May 9, 2018

Ironwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed to Unlock Shareholder Value

May 3, 2018

Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation

May 2, 2018

Ironwood Pharmaceuticals Files Definitive Proxy Materials and Mails Letter to Shareholders

Copyright © 2020, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.